CRB-913 - (CANYON-1)

Sept. 14, 2026: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported positive topline Phase 1b CANYON-1 data for CRB-913, an oral peripherally restricted CB1 inverse agonist, in obesity. In the 254-patient, 16-week, double-blind, placebo-controlled, dose-ranging study (12 weeks dosing; NCT07310901), CRB-913 produced statistically significant weight loss at all doses versus placebo: 2.8% at 20 mg, 3.3% at 40 mg, and 5.0% at 60 mg at week 12 (all p<0.0001), with no plateau observed.

At 60 mg, all study completers lost weight; 44.4% lost at least 5.0% from baseline, 6.7% lost more than 7.5%, and the maximum recorded loss was 13.4%. CRB-913 was generally well tolerated. Discontinuations due to adverse events were 3.1%-13.1%. Psychiatric adverse events were infrequent, mild to moderate, and transient, with no serious or severe psychiatric events, no suicidality, and one transient moderate depressive symptom among 188 treated participants. GI adverse events were mild or moderate with no serious or severe cases.

Next catalysts: detailed data will be presented in a late-breaking presentation at ObesityWeek 2026 (November 14-17, 2026); the company plans FDA discussions on development and expects to start a Phase 2 monotherapy study in 1H 2027.